4/9/2012 8:12:11 AM
An early peek at data from a closely watched mid-stage study combining hepatitis C drugs from Bristol-Myers Squibb(BMY_) and Gilead Sciences(GILD_) has leaked in advance of the European Association for the Study of the Liver (EASL) annual meeting. Ninety-seven percent of genotype 1 hepatitis C patients treated with Bristol's daclatasvir and Gilead's GS-7977 has undetectable viral levels after 12 weeks of treatment. For genotype 2/3 patients, the 12-week response rate was 90%, according to a research note published Monday by Jefferies analyst Thomas Wei.
comments powered by